Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 May 10;26(14):2384-9.
doi: 10.1200/JCO.2007.14.7207.

Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups

Odile Oberlin  1 , Annie Rey, Elizabeth Lyden, Gianni Bisogno, Michael C G Stevens, William H Meyer, Modesto Carli, James R Anderson
Affiliations
Randomized Controlled Trial

Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups

Odile Oberlin et al. J Clin Oncol. .

Abstract

Purpose: To identify risk factors associated with outcome in children with metastatic rhabdomyosarcoma in a large cohort of patients

Patients and methods: Pooled data were obtained from 788 patients treated in nine studies performed by European and American cooperative groups. Clinical factors, including age, histology, site of primary, and site(s) and number of sites of metastatic disease, were correlated with event-free survival (EFS) and overall survival (OS).

Results: Seven hundred eighty-eight patients were eligible for analysis. The 3-year OS and EFS were 34% (SE, 1.7) and 27% (SE, 1.6), respectively. By univariate analysis, 3-year EFS was significantly and adversely influenced by age, alveolar histology, location of primary tumor in unfavorable site (defined as extremity and "other" sites), presence of three or more sites of metastatic disease, and the presence of bone or bone marrow involvement. By multivariate analysis, EFS was strongly correlated to all factors except histology. Relative risks were 1.6 for age younger than 1 year or at least 10 years, 1.4 for unfavorable site of primary tumor, 1.4 for bone or bone marrow involvement, 1.4 for three or more metastatic sites. EFS was 50% for patients without any of these four adverse factors and was respectively 42%, 18%, 12%, and 5% in patients with one, two, three, or four factors (P < .0001).

Conclusion: This analysis identified subsets of patients with metastatic rhabdomyosarcoma with different outcomes to current therapy and offers a strategy to define patient candidates for experimental approaches to treatment.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Overall survival and event-free survival of all 788 patients.
Fig 2.
Fig 2.
Event-free survival of patients according to number of unfavorable prognostic factors. The relative risks of event are respectively 1, 1.02, 1.9, 2.3, and 3.5.
Fig 3.
Fig 3.
Event-free survival of patients according to risk score.
See this image and copyright information in PMC

References

    1. Crist W, Gehan EA, Ragab AH, et al: The third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13:610-630, 1995 - PubMed
    1. Koscielniak E, Harms D, Henze G, et al: Results of treatment for soft tissue sarcoma in childhood and adolescence: A final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol 17:3706-3719, 1999 - PubMed
    1. Stevens MC, Rey A, Bouvet N, et al: Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: Third study of the International Society of Paediatric Oncology–SIOP malignant mesenchymal tumor 89. J Clin Oncol 23:2618-2628, 2005 - PubMed
    1. Breitfeld PP, Lyden E, Raney RB, et al: Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: A report from the Intergroup Rhabdomyosarcoma Study Group. J Pediatr Hematol Oncol 23:225-233, 2001 - PubMed
    1. Breneman JC, Lyden E, Pappo AS, et al: Prognostic factors and clinical outcomes in children and adolescents with metastatic Rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 21:78-84, 2003 - PubMed

Publication types